Silence Therapeutics initiated with an Outperform at BMO Capital

BMO Capital analyst Kostas Biliouris initiated coverage of Silence Therapeutics with an Outperform rating and $67 price target. Silence is a clinical-stage company developing a competitive siRNA therapy in a condition that affects 70M people in the U.S. but has no approved therapy, the analyst tells investors in a research note. The firm says the company’s zerlasiran demonstrated up to 100% Lp(a) reduction in clinic, a target that is linked to cardiovascular risk.